These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 16395296

  • 21. FDA post-marketing safety decisions.
    Klein DF.
    J Clin Psychiatry; 2006 Aug; 67(8):1305-6. PubMed ID: 16965212
    [No Abstract] [Full Text] [Related]

  • 22. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R.
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005 Aug; (123):41-5. PubMed ID: 16541751
    [Abstract] [Full Text] [Related]

  • 23. News coverage of FDA warnings on pediatric antidepressant use and suicidality.
    Barry CL, Busch SH.
    Pediatrics; 2010 Jan; 125(1):88-95. PubMed ID: 19969614
    [Abstract] [Full Text] [Related]

  • 24. Risk of adverse behavioral effects with pediatric use of antidepressants.
    Goodman WK, Murphy TK, Storch EA.
    Psychopharmacology (Berl); 2007 Mar; 191(1):87-96. PubMed ID: 17180618
    [Abstract] [Full Text] [Related]

  • 25. Antidepressant drugs and the risk of suicide in children and adolescents.
    Isacsson G, Rich CL.
    Paediatr Drugs; 2014 Apr; 16(2):115-22. PubMed ID: 24452997
    [Abstract] [Full Text] [Related]

  • 26. Suicidality as a possible side effect of antidepressant treatment.
    Culpepper L, Davidson JR, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL.
    J Clin Psychiatry; 2004 Jun; 65(6):742-9. PubMed ID: 15291649
    [No Abstract] [Full Text] [Related]

  • 27. Antidepressants in adult suicides in New York City: 2001-2004.
    Leon AC, Marzuk PM, Tardiff K, Bucciarelli A, Stajic M, Piper TM, Galea S.
    J Clin Psychiatry; 2007 Sep; 68(9):1399-403. PubMed ID: 17915979
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses.
    Leon AC.
    Am J Psychiatry; 2007 Dec; 164(12):1786-9. PubMed ID: 18056231
    [No Abstract] [Full Text] [Related]

  • 33. Impact of the FDA black box warning on physician antidepressant prescribing and practice patterns: opening Pandora's suicide box.
    Lineberry TW, Bostwick JM, Beebe TJ, Decker PA.
    Mayo Clin Proc; 2007 Apr; 82(4):518-20. PubMed ID: 17418083
    [No Abstract] [Full Text] [Related]

  • 34. The contribution of pharmacoepidemiology to the antidepressant-suicidality debate in children and adolescents.
    Bridge JA, Axelson DA.
    Int Rev Psychiatry; 2008 Apr; 20(2):209-14. PubMed ID: 18386214
    [Abstract] [Full Text] [Related]

  • 35. The impact of the Food and Drug Administration Modernization Act on the recruitment of children for research.
    Sharav VH.
    Ethical Hum Sci Serv; 2003 Apr; 5(2):83-108. PubMed ID: 15279010
    [Abstract] [Full Text] [Related]

  • 36. Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified.
    Spielmans GI, Spence-Sing T, Parry P.
    Front Psychiatry; 2020 Apr; 11():18. PubMed ID: 32116839
    [Abstract] [Full Text] [Related]

  • 37. Regulatory and scientific issues in studies to evaluate sexual dysfunction in antidepressant drug trials.
    Khin NA, Kronstein PD, Yang P, Ishida E, Hung HM, Mathis MV, Unger EF, Temple RJ.
    J Clin Psychiatry; 2015 Aug; 76(8):1060-3. PubMed ID: 26214346
    [Abstract] [Full Text] [Related]

  • 38. Congress investigates FDA's handling of antidepressant safety information.
    Young D.
    Am J Health Syst Pharm; 2004 Nov 01; 61(21):2228, 2230, 2232 passim. PubMed ID: 15552624
    [No Abstract] [Full Text] [Related]

  • 39. Suicidality in adolescents being treated with antidepressant medications and the black box label: position paper of the Society for Adolescent Medicine.
    Lock J, Walker LR, Rickert VI, Katzman DK, Society for Adolescent Medicine.
    J Adolesc Health; 2005 Jan 01; 36(1):92-3. PubMed ID: 15702497
    [No Abstract] [Full Text] [Related]

  • 40. The Food and Drug Administration's deliberations on antidepressant use in pediatric patients.
    Leslie LK, Newman TB, Chesney PJ, Perrin JM.
    Pediatrics; 2005 Jul 01; 116(1):195-204. PubMed ID: 15995053
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.